AAAAAA

   
Results: 1-15 |
Results: 15
Antibody targeting of tumor vasculature
Authors: Wilson, J West, DC Thorpe, PE
Citation: J. Wilson et al., Antibody targeting of tumor vasculature, NEW ANGIOTHERAPY, 2002, pp. 475-489
Generation and characterization of recombinant vascular targeting agents from hybridoma cell lines
Authors: Gottstein, C Wels, W Ober, B Thorpe, PE
Citation: C. Gottstein et al., Generation and characterization of recombinant vascular targeting agents from hybridoma cell lines, BIOTECHNIQU, 30(1), 2001, pp. 190
VEGF-VEGF receptor complexes as markers of tumor vascular endothelium
Authors: Brekken, RA Thorpe, PE
Citation: Ra. Brekken et Pe. Thorpe, VEGF-VEGF receptor complexes as markers of tumor vascular endothelium, J CONTR REL, 74(1-3), 2001, pp. 173-181
The angiogenic pathway 'vascular endothelial growth factor/flk-I (KDR)-receptor' in rheumatoid arthritis and osteoarthritis
Authors: Giatromanolaki, A Sivridis, E Atanassou, N Zois, E Thorpe, PE Brekken, RA Gatter, KC Harris, AL Koukourakis, IM Koukourakis, MI
Citation: A. Giatromanolaki et al., The angiogenic pathway 'vascular endothelial growth factor/flk-I (KDR)-receptor' in rheumatoid arthritis and osteoarthritis, J PATHOLOGY, 194(1), 2001, pp. 101-108
Vascular endothelial growth factor isoforms display distinct activities inpromoting tumor angiogenesis at different anatomic sites
Authors: Guo, P Xu, L Pan, S Brekken, RA Yang, ST Whitaker, GB Nagane, M Thorpe, PE Rosenbaum, JS Huang, HJS Cavenee, WK Cheng, SY
Citation: P. Guo et al., Vascular endothelial growth factor isoforms display distinct activities inpromoting tumor angiogenesis at different anatomic sites, CANCER RES, 61(23), 2001, pp. 8569-8577
The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma - Prognostic and therapeutic implications
Authors: Giatromanolaki, A Sivridis, E Brekken, R Thorpe, PE Anastasiadis, P Gatter, KC Harris, AL Koukourakis, MI
Citation: A. Giatromanolaki et al., The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma - Prognostic and therapeutic implications, CANCER, 92(10), 2001, pp. 2569-2577
Tumor infarction by targeting tissue factor to tumor vasculature
Authors: Thorpe, PE Ran, S
Citation: Pe. Thorpe et S. Ran, Tumor infarction by targeting tissue factor to tumor vasculature, CANCER J, 6, 2000, pp. S237-S244
Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways
Authors: Giatromanolaki, A Koukourakis, MI Sivridis, E O'Byrne, K Cox, G Thorpe, PE Gatter, KC Harris, AL
Citation: A. Giatromanolaki et al., Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways, CLIN CANC R, 6(5), 2000, pp. 1917-1921
Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas
Authors: Giatromanolaki, A Koukourakis, MI Sivridis, E Thorpe, PE Brekken, RA Konstantinos, S Fountzilas, G Gatter, KC Harris, AL
Citation: A. Giatromanolaki et al., Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas, CLIN EXP M, 18(4), 2000, pp. 313-319
Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors
Authors: Feng, D Nagy, JA Brekken, RA Pettersson, A Manseau, EJ Pyne, K Mulligan, R Thorpe, PE Dvorak, HF Dvorak, AM
Citation: D. Feng et al., Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors, J HIST CYTO, 48(4), 2000, pp. 545-555
Selective inhibition of vascular endothelial growth factor (VEGF) receptor2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice
Authors: Brekken, RA Overholser, JP Stastny, VA Waltenberger, J Minna, JD Thorpe, PE
Citation: Ra. Brekken et al., Selective inhibition of vascular endothelial growth factor (VEGF) receptor2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice, CANCER RES, 60(18), 2000, pp. 5117-5124
Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer
Authors: Koukourakis, MI Giatromanolaki, A Thorpe, PE Brekken, RA Sivridis, E Kakolyris, S Georgoulias, V Gatter, KC Harris, AL
Citation: Mi. Koukourakis et al., Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer, CANCER RES, 60(11), 2000, pp. 3088-3095
Endovascular therapy for chronic venous obstruction
Authors: Thorpe, PE
Citation: Pe. Thorpe, Endovascular therapy for chronic venous obstruction, CHRONIC VENOUS INSUFFICIENCY, 2000, pp. 179-193
Standing surgical repair of cystorrhexis in two mares
Authors: Rodgerson, DH Spirito, MA Thorpe, PE Hanson, RR
Citation: Dh. Rodgerson et al., Standing surgical repair of cystorrhexis in two mares, VET SURGERY, 28(2), 1999, pp. 113-116
Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance
Authors: Huang, XM Gottstein, C Brekken, RA Thorpe, PE
Citation: Xm. Huang et al., Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance, BIOC BIOP R, 252(3), 1998, pp. 643-648
Risultati: 1-15 |